Haselmeier, Common Sensing to Partner on Injectable Solutions
The companies will partner to develop smart connected monitoring and support solutions for injectable drugs.
On May 3, 2018, Haselmeier, a Swiss-based developer and manufacturer of self-injection devices, and Common Sensing, a Cambridge, MA-based smart injector monitoring and support solutions company, announced a partnership to develop smart connected monitoring and support solutions for injectable drugs.
Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology to create a smart disposable injector pen platform, which will be available in 2019. The platform will be sold by Haselmeier.
The smart injector pen will record the time and amount of every injector dose as well as other information, such as storage temperature. Gocap information may be made available for users, caretakers, clinicians, healthcare systems, researchers, and pharmaceutical companies, according to Haselmeiner.
“There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy. The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives,” said Frédéric Gabriel, chief strategy officer at Haselmeier, in a company press release.
Source: Haselmeier
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
